News Related to Relapsed or Refractory Acute Leukemia

Related coverage linked through entity extraction aliases.

Syndax Pharmaceuticals Expands Revuforj Access and Reports Strong Commercial Performance

Mar 19, 2026

Syndax Pharmaceuticals announced a collaboration to expand global access to Revuforj while reporting strong commercial performance for its two marketed products, with Revuforj generating $125 million and Niktimvo $152 million in the first 11 months of sales.

Syndax Pharmaceuticals Expands Revuforj Access, Receives Price Target Increase

Feb 14, 2026

Syndax Pharmaceuticals partnered with World Orphan Drug Alliance to launch a Managed Access Program for Revuforj in multiple regions. A price target was raised to $28 while maintaining a Buy rating.